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Abstract
Antimicrobial-resistant   is a global public health problemNeisseria gonorrhoeae
in the 21st century.   has developed resistance to all classes ofN. gonorrhoeae
antibiotics used for empirical treatment, and clinical treatment failure caused by
extensively resistant strains has been reported. Identifying specific factors
associated with an increased risk of antimicrobial-resistant N. gonorrhoeae
might help to develop strategies to improve antimicrobial stewardship. In this
review, we describe the findings of 24 studies, published between 1989 and
2017, that examined epidemiological, behavioural, and clinical factors and their
associations with a range of antimicrobial agents used to treat gonorrhoea.
Antimicrobial-resistant  is more common in older than youngerN. gonorrhoeae 
adults and in men who have sex with men compared with heterosexual men
and women. Antimicrobial-resistant  is less common in someN. gonorrhoeae 
black minority and Aboriginal ethnic groups than in the majority white
population in high-income countries. The factors associated with
antimicrobial-resistant gonorrhoea are not necessarily those associated with a
higher risk of gonorrhoea.
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Introduction
Antimicrobial-resistant Neisseria gonorrhoeae (AMR-NG) is a 
global public health challenge1. The World Health Organization 
(WHO) estimates that, in 2012, more than 78 million new infec-
tions with gonorrhoea occurred worldwide2. Of these, more than 
90% were in low- and middle-income countries. In high-income 
countries, including England3, the USA4 and Australia5, N. gon-
orrhoeae is the second most commonly reported bacterial sexu-
ally transmitted infection (STI). N. gonorrhoeae primarily infects 
the mucosal epithelium, causing urethritis in men, cervicitis in 
women, and rectal and pharyngeal infection in men who have sex 
with men (MSM) and women6. Untreated infection that spreads 
to the upper genital tract can cause epididymo-orchitis and pelvic 
inflammatory disease, ectopic pregnancy, and tubal infertility6. 
Infection in pregnancy is associated with preterm birth and low 
birthweight and can cause neonatal conjunctivitis if transmitted 
during delivery. Rarely, N. gonorrhoeae can spread systemically, 
causing arthritis, endocarditis, and septicaemia. The inflamma-
tory response to N. gonorrhoeae in the genital tract increases 
the infectivity of HIV. All of these complications will become 
more frequent if antimicrobial resistance renders gonorrhoea 
untreatable. Gonorrhoea shares some epidemiological characteris-
tics with other bacterial STIs7. It is associated with higher num-
bers of sex partners8 (which are more common in MSM than in 
heterosexual adults9,10), younger age3, and lower socioeconomic 
position11, and, in high-income countries, it is associated with 
being a member of some black and ethnic minority groups11.
N. gonorrhoeae is a bacterium that has extensive capacity 
for genetic mutation or plasmid exchange of resistant genes 
throughout its life cycle1. This remarkable biological charac-
teristic has helped the bacteria to survive and evolve or acquire 
resistance to many different classes of antibiotics over the years1. 
Unemo and Shafer have reviewed antimicrobial treatments for 
gonorrhoea and the emergence of resistance comprehensively up 
to 20141. Penicillin was first used to treat gonorrhoea in 1943. Ini-
tially, chromosomally mediated resistance emerged, so higher and 
higher doses were needed to cure gonorrhoea. In 1976, the first plas-
mid-mediated penicillinase-producing strains were reported from 
South East Asia and West Africa12,13. In the 1990s, quinolones, par-
ticularly the fluoroquinolone ciprofloxacin, replaced penicillin as 
the first-line treatment for gonorrhoea14. Resistance was reported 
initially from countries in South East Asia and spread interna-
tionally by the early to mid-2000s. Third-generation, extended-
spectrum cephalosporins (ESCs) (mostly oral cefixime and 
injectable ceftriaxone) have been recommended for first-line use 
since the early 2000s. Resistance to ESCs was reported first in 
Japan15, and strains with high-level resistance to ESCs spread to 
Europe16–19. Currently, the WHO recommends dual therapy with 
ceftriaxone and azithromycin for the first-line treatment of gon-
orrhoea, and the intention is to ensure cure rates of greater than 
95% of infections20. Clinical treatment failure and high-level resist-
ance to this regimen were reported in 201617. Resistance has also 
emerged to other drugs, such as tetracyclines, spectinomycin, 
and azithromycin, that have not been used widely as first-line 
treatments.
Antimicrobial resistance hampers strategies to control and 
prevent gonorrhoea21. Understanding factors that are associated 
with AMR-NG could help to identify groups at high risk of hav-
ing resistant infections, provide more focused management, and 
assist antimicrobial stewardship. In this review, we describe the 
findings of studies that have examined associations between epi-
demiological, behavioural, and clinical factors and the presence 
of AMR-NG.
Search strategy
We searched Medline (Ovid, Wolters Kluwer) from 1946 until 
August 2017 without language restrictions by using combinations 
of keywords for the organism, AMR, and associated factors: Neis-
seria gonorrhoeae or gonorrhoea, drug resistance, risk factors, 
sexual behaviour, health services, or epidemiology. We selected 
studies that compared epidemiological, behavioural, or clinical 
factors in people with or without AMR-NG. We recorded informa-
tion about study characteristics, study population, antimicrobials, 
and findings from each study in an evidence table (Appendix 1).
Characteristics of included studies
Of 129 articles identified, 24 publications were included14,22–44. 
Appendix 1 summarises the main characteristics of each study. 
All included studies used a cross-sectional (16 studies) or case-
control (eight studies) study design. Nine studies were nested in 
surveillance systems for AMR-NG23,25,28,30,32,37–39,44, and 14 reported 
a multivariable analysis23–25,27,28,30,31,35,36,39,40,42–44. The evidence that 
we found about factors associated with AMR-NG comes mainly 
from regions and countries that do not have the highest incidence 
of gonorrhoea (Table 1). Of 24 included studies, 19 came from 
Europe23,25,27–29,35,37,40,42–44 and North America14,22,26,30,33,38,39,41, 
although the WHO European Region and the whole WHO Region 
of the Americas account for only 20% of people with incident 
gonorrhoea worldwide2. These regions include countries with the 
best-established surveillance systems for STIs in general and sys-
tematic surveillance systems for antimicrobial resistance, such 
as the Gonococcal Resistance to Antimicrobials Surveillance 
Programme (GRASP) in England and Wales23, the US Gonococ-
cal Isolate Surveillance Program (GISP)30, and the Australian 
Gonococcal Surveillance Programme (AGSP)32. These systems 
can collect demographic and epidemiological data so that asso-
ciations with AMR-NG can be assessed regularly. Our search did 
not find any studies about potential risk factors for AMR-NG from 
Africa, where the prevalence and incidence of gonorrhoea are 
high2, or from Latin America and the Caribbean, South East Asia, 
or Eastern Mediterranean regions, where surveillance for STIs 
and AMR is also limited. Although AMR-NG strains with resist-
ance to penicillin (penicillinase-producing), spectinomycin, fluo-
roquinolones, and ESCs were first reported from countries in 
the Western Pacific region, such as Japan, South Korea, and the 
Philippines45, we found only three studies in the region that 
examined factors associated with AMR-NG: two in China24,36 and 
one in the Philippines31.
Figure 1 shows the distribution of studies that have exam-
ined potential risk factors for AMR-NG over time, according 
to antibiotic class. Broadly speaking, these follow the periods in 
which each antimicrobial class was a recommended treatment. 
The first studies, published in 1989, examined risk factors for 
penicillin resistance and for tetracycline, which was beginning 
to be used to treat chlamydia infections and non-specific genital 
Page 3 of 11
F1000Research 2018, 7(F1000 Faculty Rev):400 Last updated: 27 MAR 2018
Table 1. Estimated numbers of new gonorrhoea cases, countries reporting Neisseria gonorrhoeae 
resistance, and number of studies about risk factors by WHO region.
WHO regiona(number of 
countries in the region)
Number of 
new cases of 
gonorrhoea, 2012b
Countries reporting resistance for at 
least one year from 2009 to 2014c
Number of 
publications 
in reviewCiprofloxacin Azithromycin ESC
African region 
(46 countries) 11,440 6/8 3/3 1/9 0
Region of the Americas 
(35 countries) 10,974 14/16 2/7 0/16
North America 8
Latin America and 
Caribbean 0
Eastern Mediterranean 
region (21 countries) 4,526 0/1 0/1 0/3 0
European region 
(53 countries) 4,686 23/26 21/26 15/27 11
South East Asia region 
(11 countries) 11,407 2/6 1/6 4/6 0
Western Pacific region 
(27 countries) 35,247 7/15 2/15 6/16
Australia 2
Rest of Western Pacific 3
aRegion of the Americas divided into countries of North America and Latin America and the Caribbean; all studies in the 
review were in North America. The Western Pacific region subdivided into Australia and all other countries in the region; 
two out of five studies were from Australia. 
bEstimates from the World Health Organization (WHO)2. The point estimate for each region is given. Numbers of cases for 
the subdivided regions are not known.
cFrom WHO global gonococcal antimicrobial surveillance programme (GASP)21. Numbers are the number of countries 
reporting resistance of at least 5%/total number countries reporting to GASP. ESC, extended-spectrum cephalosporin.
Figure 1. Number of studies found about factors associated with antimicrobial-resistant Neisseria gonorrhoeae from 1989 to 2017, 
according to class of antimicrobial.
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infections22,33. The next, and largest, group of studies focused on 
the identification of factors potentially associated with resistance 
to fluoroquinolones14,26,29,31,39–41, followed by macrolides25,27,37,38 
and ESCs23–25,27,28,35–37,42.
Factors potentially associated with antimicrobial-
resistant Neisseria gonorrhoeae
We describe epidemiological, behavioural, and clinical factors that 
have been examined in association with AMR-NG (summarised 
in Appendix 2). We describe as ‘risk factors’ factors associated 
with an increased risk or odds of AMR-NG, based on the effect 
size and its 95% confidence intervals (CIs), where available. Our 
overall interpretation takes into account the size of the study and 
the type of statistical analysis. Where findings between studies 
are inconsistent, we give more emphasis to findings from larger 
studies with multivariable analyses that control for important 
potential confounding factors. For most factors examined, there 
were too few studies to determine whether associations differ for 
different antimicrobials. In observational studies, confounding of 
observed associations by measured or unmeasured factors is likely.
Epidemiological factors
Age. Younger age is a risk factor for gonorrhoea; the peak age 
groups for diagnosis of gonorrhoea are 20–24 years in both 
women and men in the USA4 and 20–24 in women and 25–35 in 
men in England3. Amongst MSM, the peak age at infection is 
somewhat older3.
In contrast, AMR-NG was more common in adults who were 
25 years or older than in younger people in most studies that exam-
ined age as a risk factor for resistance to tetracyclines, fluoroqui-
nolones, and ESCs (Appendix 2). This finding might have resulted 
from the inclusion of large numbers of MSM; in two large stud-
ies, age was no longer associated with decreased susceptibility 
to ESCs in multivariable analyses adjusted for the composition 
of the study population23,42. In several studies, however, older age 
remained associated with AMR-NG in multivariable analyses, 
including ciprofloxacin resistance in women in the Netherlands44; 
reduced susceptibility to ceftriaxone in heterosexual men and 
women, but not MSM, in England and Wales28; ciprofloxacin 
resistance in Spain35; ciprofloxacin and cefixime but not azithro-
mycin resistance in a European Union surveillance network25; and 
probable resistance to ceftriaxone but not to penicillin or 
tetracycline in China24. Studies that found no association or an 
association with younger age were small or methodologically 
flawed36.
Sex. Gonorrhoea surveillance reports show higher numbers of 
reported cases of gonorrhoea in men than in women3–5, even after 
the high proportion of infections diagnosed in MSM was taken 
into account3,4. The higher frequency of symptomatic infections 
in men than in women results in higher levels of attendance at 
healthcare settings6. We found 11 studies that compared AMR-
NG between heterosexual men and women14,23–25,27–29,33,35,36,41. Three 
publications from two studies with multivariable analyses found 
AMR-NG more commonly in heterosexual men than in 
women23,24,28. Heterosexual men had about twice the odds of NG 
with reduced susceptibility to ceftriaxone than did women in 
China24 and in England and Wales23,28 and of chromosomal resist-
ance to tetracycline in China (adjusted odds ratio [OR] 2.73, 
95% CI 1.06–7.05)24.
Same-sex sexual partnerships in men. Gonorrhoea is more com-
monly reported in MSM than in men who have sex with women 
only or in women46, and rates of reported gonorrhoea are increas-
ing more rapidly in MSM than in men who have sex with women 
only or in women46,47. Most studies that have examined this 
factor14,23,35,44 also found that AMR-NG was more common in MSM 
than in men who have sex with women only, including most stud-
ies with multivariable analyses23,35,42,44. AMR-NG was more com-
monly found in MSM compared with men who have sex with 
only women in the Netherlands for cefotaxime (age-adjusted 
OR 2.9, 95% CI 1.4–5.8)42 and ciprofloxacin (adjusted OR 2.0, 
95% CI 1.5–2.6)44, in England and Wales for cefixime (adjusted 
OR 5.47, 95% CI 3.99–7.48)23, and in some but not all counties 
in California (USA) for ciprofloxacin39. It has been hypothesised 
that, in the USA, the emergence of resistance to ciprofloxacin 
started in MSM and spread to men who have sex with women 
only30. In the European Gonococcal Antimicrobial Resistance 
Programme (Euro-GASP), covering more than 20 countries, 
AMR-NG was reported to be more common among heterosex-
ual men than among MSM25,37. The reasons for the discrepant 
findings are not clear because the data were aggregated across 
all countries and were missing from nearly half of the records25.
AMR-NG might also be common in MSM because the pharynx 
is thought to be a reservoir for strains that have acquired genes 
that confer resistance to ESCs in commensal Neisseria species 
(see ‘Anatomical site of infection’ subsection of ‘Clinical fac-
tors’ section)1. MSM can have gonococcal infection in the phar-
ynx and rectum, resulting from oral and anal sexual intercourse, 
as well as the urethra6,48. Pharyngeal and rectal gonorrhoea are 
usually asymptomatic and can remain untreated if these ana-
tomical sites are not sampled49. Anatomical site of infection is 
considered as a risk factor below.
Racial or ethnic group. Surveillance reports show that rates of 
gonorrhoea diagnoses are several times higher in some minori-
ties, such as African American, black Caribbean, and indigenous 
Aboriginal ethnic groups, than in the majority white population in 
countries such as the USA4, the UK3, the Netherlands50, Canada26, 
and Australia5. We found eight studies that examined racial or eth-
nic group as a risk factor14,23,26–28,32,39,44. AMR-NG was not more 
common in black and Aboriginal ethnic groups. Ciprofloxacin 
resistance was less common in people from black, Hispanic, and 
other ethnic groups than in whites in a multivariable analysis in 
the USA39 and less common in people from Aboriginal groups 
in Canada in a univariable analysis26. Decreased susceptibility 
was less common in people from ethnic groups in multivariable 
analyses in England and Wales23,28. In Australia, surveillance data 
from the Northern Territories and Western Australia showed a 
much lower proportion of penicillinase-producing NG isolates 
in remote areas (2%), in which the population is almost entirely 
Aboriginal, than in urban areas (14–19%), where the population is 
mixed32. However, in the USA, ciprofloxacin was slightly more 
common in people from Asian and Pacific Island ethnic groups 
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than in whites14,39. Assortative sexual mixing patterns, in which 
people are more likely to have partners from their own than from 
other ethnic groups51, are likely to contribute to differential rates 
of both gonorrhoea infection and maybe also AMR-NG.
Socioeconomic position. Whilst higher rates of reported gonor-
rhoea are strongly associated with lower socioeconomic position, 
possibly as a marker of poor education and awareness of STIs11 
and limited access to healthcare, we found only one study that 
had examined the association with AMR-NG. In one study in 
China, higher income levels were associated with lower levels 
of plasmid-mediated tetracycline resistance (adjusted OR 0.34, 
95% CI 0.14–0.18) but not ceftriaxone or penicillin resistance24.
Behavioural factors
Multiple sex partners. Gonorrhoea has a short duration of 
infectiousness, and its persistence in a population relies on 
transmission in groups with high rates of sexual partner change8. 
The probability of acquiring AMR-NG, however, is not necessar-
ily associated with higher numbers of sexual partners when other 
factors are taken into consideration. In several studies, a higher 
number of sexual partners was associated with AMR-NG in 
univariable analysis22–24,27,28,35,38,40. In studies that conducted mul-
tivariable analyses23,27,35, only one study, in the Netherlands, 
found that the association persisted, with an attenuated OR27.
Sex with partners abroad. Travel abroad has been reported in 
some studies as a risk factor for STIs52,53, presumably because peo-
ple take more risks when on holiday, such as having unprotected 
sex with casual partners54. Since AMR-NG often arises first in 
countries in South East Asia and the Western Pacific, travellers, 
including sex tourists, who have unprotected sex in these regions 
are assumed to import AMR-NG into their home countries45,55. We 
found 10 studies that investigated travel or sexual contact abroad 
as a risk factor for AMR-NG14,23,27–30,35,38,39,43, and four of them 
examined fluoroquinolone resistance in the late 1990s and early 
2000s14,30,39,43. Ciprofloxacin resistance was more common in 
those reporting travel abroad or sex with a partner who had trav-
elled abroad in univariable analyses from Hawaii14 and California39 
but not in multivariable analysis39. A national study in the USA 
found higher levels of fluoroquinolone resistance in heterosexual 
men with a history of travel but found lower levels in MSM30. 
Another study found an association, in multivariable analysis, 
with sexual contact outside Switzerland43. The variables in these 
studies do not specify exposures in particular places and might 
underestimate associations. Supportive evidence about the inter-
national spread of AMR-NG comes from gene sequencing stud-
ies of some highly resistant N. gonorrhoeae clonal strains18. More 
detailed studies on people with gonorrhoea and their sexual net-
works with detailed phenotypic and genotypic characterisation 
would contribute to the identification of the origin and spread 
of resistance.
Exchanging sex for money. Commercial sex workers and their 
clients in some countries are at high risk of acquiring STIs, 
including gonorrhoea1. We included seven studies that consid-
ered commercial sex and AMR-NG14,22,31,33,38,39,44. One of these 
studies, conducted among female commercial sex workers in 
the Philippines from 1996 to 1997, found that, in multivariable 
analysis, high-level resistance to ciprofloxacin was associated 
with living in the capital, Manila, and having recently started sex 
work31. One study in the Netherlands found that, in multivari-
able analysis, female sex workers had a much higher risk of 
ciprofloxacin-resistant gonorrhoea than did other women (adjusted 
OR 25.0, 95% CI 7.7–78.2)44. Studies in the USA did not 
distinguish clearly between female or male sex workers or 
clients14,22,38,39; exposure to commercial sex work was associated 
with AMR-NG in univariable analysis in only two studies22,38.
Alcohol and drug use. Only four of the included studies22,24,38,39 
looked at these factors. One study in China found that alcohol use 
was associated with tetracycline resistance (adjusted OR 1.69, 
95% CI 1.08–2.64)24 in multivariable analysis. In the USA, one 
study found that having had a sex partner who received drugs or 
money for sex was associated with azithromycin resistance 
(crude OR 34.0, 95% CI 2.3–1651)38, but another study found a 
much weaker association with ciprofloxacin resistance in univari-
able analysis and no association in multivariable analysis39. These 
factors warrant more detailed investigation.
Clinical factors
Anatomical site of infection. MSM and commercial sex work-
ers can harbour N. gonorrhoeae in the pharynx1,6. We found 
three studies25,27,28 that considered anatomical site of infection. 
All three studies conducted multivariable analysis. In the 
Netherlands, ceftriaxone resistance was more common in the phar-
ynx than in the urethra amongst MSM (adjusted OR 2.52, 95% CI 
1.64–3.89) but not heterosexual women and men27, and in England 
and Wales, a slight decrease in susceptibility to ceftriaxone was more 
common in the pharynx in heterosexual women and men (adjusted 
OR 1.84, 95% CI 1.44–2.34) but not MSM23. In Euro-GASP, iso-
lates from the pharynx were not more likely than genital isolates to 
show AMR-NG, but cefixime and ciprofloxacin resistance were 
reported to be less common in anorectal than in genital isolates25.
Co-infection with HIV and other sexually transmitted infec-
tions. People infected with NG are at higher risk of acquiring HIV 
infection56. Being co-infected with HIV was associated with resist-
ance to ESCs or ciprofloxacin in univariable but not multivariable 
analysis in three studies in the Netherlands and in England and 
Wales23,42,44. In another study in the Netherlands, MSM with 
HIV infection were less likely than HIV-negative MSM to have 
azithromycin resistance (adjusted OR 0.72, 95% CI 0.54–0.96) 
in multivariable analysis27. Co-infection with Chlamydia tra-
chomatis is also common in people with gonorrhoea. In studies 
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conducted by GRASP in England and Wales23,28, people who were 
not co-infected with chlamydia were more likely to have AMR-NG 
in multivariable analyses. There is no definitive explanation for 
this finding.
Recent antibiotic use. Antimicrobial use exerts selection 
pressure for the emergence of resistance1. Current or recent anti-
microbial use was examined in five studies in the USA, but find-
ings were inconsistent14,22,33,38,39. Ciprofloxacin resistance was found 
more commonly in female sex workers in the Philippines who 
were taking antimicrobials in univariable but not multivariable 
analysis31. Studies that did not find associations with past anti-
microbial use might have asked questions that were not specific 
enough about particular antimicrobials.
Other risk factors
Additional factors—such as gonorrhoea or STI history, lifetime 
sex partners, partnership type, more than one infected site, and 
year of isolation—that were reported in small numbers of studies 
are listed in Appendix 2 but are not described in detail here.
Discussion
In this review, AMR-NG was more common in older than in 
younger adults, in heterosexual men than in women, in MSM 
compared with men who have sex with women only, and possi-
bly in people with poor socioeconomic position. People from 
some black ethnic groups in the USA and Europe and Aborigi-
nal ethnic groups living in Canada and Australia are less likely to 
have AMR-NG than the white majority population. Very few stud-
ies about risk factors for AMR-NG have been done in countries 
in sub-Saharan Africa, Latin America, or some parts of South 
East Asia and the Western Pacific where gonorrhoea is most 
common.
The main strength of this review is that we searched for stud-
ies worldwide, irrespective of the language and the year of pub-
lication, and we extracted the same information from all studies. 
The main limitation of the review is that it was not entirely 
systematic. Our search of Medline might have missed studies, 
particularly from low- and middle-income countries, non-English 
language journals, and grey literature. Therefore, the findings of 
the review are most applicable to factors associated with anti-
microbial-resistant gonorrhoea in high-income countries in 
Europe, North America, and Australia. We did not follow a proto-
col, and, although we selected factors of interest in advance, we 
did not report all study findings comprehensively. Nevertheless, 
our interpretation took into account studies that found no asso-
ciation with a potential risk factor and we distinguished between 
associations found only in univariable analyses and those found 
consistently in multivariable analyses that control for potential 
confounding factors.
This review shows that some risk factors for AMR-NG are not 
necessarily those associated with a higher risk of gonorrhoea infec-
tion itself (Appendix 3). Of note, whilst the risk of gonorrhoea 
in heterosexual adults is highest amongst younger people with 
high numbers of sexual partners, AMR-NG appears to be more 
common in older adults and, after other factors were controlled 
for, high numbers of sexual partners were not consistently asso-
ciated with AMR-NG. AMR-NG was also less likely amongst 
people from black minority and Aboriginal ethnic groups living 
in countries where the majority of the population is from white 
ethnic groups. These findings appeared to be consistent across 
several different antibiotic classes. We cannot provide definitive 
explanations for these findings, but they could offer some empiri-
cal support for the results of a mathematical modelling study, 
which found that a high treatment rate, rather than the rate of 
partner change, predicts the spread of AMR-NG57. Higher preva-
lence of AMR-NG in MSM could result from a combination of 
factors, including a high risk of gonorrhoea infection at 
older ages than in heterosexuals3, frequent oral sex resulting in 
pharyngeal infections6, and high attendance rates at sexual health 
clinics58.
We did not find that recent travel abroad, commonly reported 
as a risk factor for AMR-NG, was consistently associated with 
resistance. Because a history of recent travel, as asked about in 
the US GISP, is too non-specific, some studies might not have 
found an association. In addition, associations might differ over 
time and be found when resistance to a particular class of antimi-
crobials, or a specific gonococcal clone, starts to spread but might 
not be found at a later time point. Evidence from gene sequenc-
ing studies with supportive evidence from epidemiological studies 
strongly suggests that antimicrobial-resistant gonococcal strains 
appear to emerge in parts of South East Asia and are spread by 
international travellers1. Researchers have found more consist-
ent evidence of the role of travel for other organisms. A system-
atic review of cohort studies showed high levels of acquisition 
of multidrug-resistant Enterobacteriaceae in travellers returning 
from countries in southern Asia59.
Conclusions and recommendations for future 
research
This review found a limited number of studies that investi-
gated factors associated with AMR-NG and few studies from 
low- and middle-income countries where both gonorrhoea and 
antimicrobial resistance are most common. For this reason, we 
could not provide a comprehensive global picture of factors that 
increase the risk of AMR-NG. The factors associated with anti-
microbial-resistant gonorrhoea are not necessarily those associ-
ated with a higher risk of gonorrhoea. Future research studies 
should investigate in more detail the apparent associations with 
increased risk of AMR-NG in older age groups and amongst travel-
lers and with decreased risk of AMR-NG in black and Aboriginal 
groups living in high-income countries. Improvements in surveil-
lance systems for antimicrobial resistance, including enhanced 
surveillance that collects information about key factors such as age, 
same sex partnerships, travel-associated sexual partnerships, or 
sentinel surveillance in specific groups, might allow earlier identi-
fication of emerging resistance and of risk factors that could allow 
more intensive follow-up and prevention interventions in groups at 
high risk of AMR-NG21. Better knowledge about modifiable 
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risk factors for AMR-NG could help to mitigate the spread of 
resistance to ESCs, the last recommended empirical treatment for 
gonorrhoea.
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